A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisAlena Novotná, Jan Mareš, A Klimek et al.|European Journal of Neurology|2011Cited by 465